Real-life efficacy and safety of omalizumab in Portuguese patients with persistent uncontrolled asthma
M.. Pereira Barbosaa, A.. Bugalho de Almeidab, C.. Pereirac,
, C.-W. Chend, P.. Georgioue, G.. Peacheye
Corresponding author
a Serviço de Imunoalergologia, Centro Hospitalar de Lisboa Norte, Lisbon, Portugal
b Clínica Universitária de Pneumologia, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
c Novartis Farma – Produtos Farmaceuticos S.A., Avenida Professor Doutor Cavaco Silva, n.° 10E, Taguspark, 2740-255 Porto Salvo, Portugal
d Novartis Pharmaceuticals Corporation, One Health Plaza East Hanover, NJ 07936-1080, USA
e Novartis Pharmaceuticals UK Limited, Wimblehurst Road Horsham, West Sussex RH12 5AB, UK
Read
9319
Timeswas read the article
2814
Total PDF
6505
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 18 | 1 | 19 |
| 2025 5 | 108 | 47 | 155 |
| 2025 4 | 89 | 59 | 148 |
| 2025 3 | 72 | 45 | 117 |
| 2025 2 | 66 | 33 | 99 |
| 2025 1 | 57 | 36 | 93 |
| 2024 12 | 43 | 23 | 66 |
| 2024 11 | 66 | 45 | 111 |
| 2024 10 | 62 | 32 | 94 |
| 2024 9 | 64 | 25 | 89 |
| 2024 8 | 69 | 29 | 98 |
| 2024 7 | 51 | 35 | 86 |
| 2024 6 | 61 | 23 | 84 |
| 2024 5 | 45 | 31 | 76 |
| 2024 4 | 57 | 26 | 83 |
| 2024 3 | 60 | 31 | 91 |
| 2024 2 | 48 | 24 | 72 |
| 2024 1 | 41 | 24 | 65 |
| 2023 12 | 34 | 29 | 63 |
| 2023 11 | 46 | 30 | 76 |
| 2023 10 | 42 | 43 | 85 |
| 2023 9 | 31 | 29 | 60 |
| 2023 8 | 40 | 22 | 62 |
| 2023 7 | 40 | 27 | 67 |
| 2023 6 | 38 | 16 | 54 |
| 2023 5 | 64 | 23 | 87 |
| 2023 4 | 40 | 14 | 54 |
| 2023 3 | 80 | 22 | 102 |
| 2023 2 | 58 | 21 | 79 |
| 2023 1 | 47 | 22 | 69 |
| 2022 12 | 68 | 20 | 88 |
| 2022 11 | 92 | 39 | 131 |
| 2022 10 | 55 | 43 | 98 |
| 2022 9 | 34 | 27 | 61 |
| 2022 8 | 51 | 35 | 86 |
| 2022 7 | 48 | 50 | 98 |
| 2022 6 | 40 | 35 | 75 |
| 2022 5 | 47 | 35 | 82 |
| 2022 4 | 32 | 32 | 64 |
| 2022 3 | 43 | 45 | 88 |
| 2022 2 | 47 | 39 | 86 |
| 2022 1 | 31 | 35 | 66 |
| 2021 12 | 38 | 33 | 71 |
| 2021 11 | 36 | 43 | 79 |
| 2021 10 | 43 | 41 | 84 |
| 2021 9 | 31 | 34 | 65 |
| 2021 8 | 29 | 25 | 54 |
| 2021 7 | 27 | 13 | 40 |
| 2021 6 | 26 | 25 | 51 |
| 2021 5 | 33 | 26 | 59 |
| 2021 4 | 100 | 55 | 155 |
| 2021 3 | 73 | 18 | 91 |
| 2021 2 | 53 | 19 | 72 |
| 2021 1 | 34 | 11 | 45 |
| 2020 12 | 32 | 9 | 41 |
| 2020 11 | 39 | 23 | 62 |
| 2020 10 | 39 | 16 | 55 |
| 2020 9 | 59 | 28 | 87 |
| 2020 8 | 79 | 24 | 103 |
| 2020 7 | 100 | 22 | 122 |
| 2020 6 | 94 | 14 | 108 |
| 2020 5 | 100 | 22 | 122 |
| 2020 4 | 85 | 5 | 90 |
| 2020 3 | 84 | 9 | 93 |
| 2020 2 | 75 | 26 | 101 |
| 2020 1 | 89 | 19 | 108 |
| 2019 12 | 93 | 14 | 107 |
| 2019 11 | 86 | 14 | 100 |
| 2019 10 | 88 | 25 | 113 |
| 2019 9 | 77 | 28 | 105 |
| 2019 8 | 107 | 8 | 115 |
| 2019 7 | 137 | 19 | 156 |
| 2019 6 | 143 | 19 | 162 |
| 2019 5 | 121 | 8 | 129 |
| 2019 4 | 118 | 32 | 150 |
| 2019 3 | 187 | 16 | 203 |
| 2019 2 | 187 | 6 | 193 |
| 2019 1 | 167 | 26 | 193 |
| 2018 12 | 81 | 4 | 85 |
| 2018 11 | 49 | 0 | 49 |
| 2018 10 | 51 | 11 | 62 |
| 2018 9 | 19 | 12 | 31 |
| 2018 8 | 43 | 23 | 66 |
| 2018 7 | 31 | 16 | 47 |
| 2018 6 | 33 | 17 | 50 |
| 2018 5 | 47 | 25 | 72 |
| 2018 4 | 44 | 18 | 62 |
| 2018 3 | 54 | 19 | 73 |
| 2018 2 | 15 | 14 | 29 |
| 2018 1 | 18 | 14 | 32 |
| 2017 12 | 21 | 32 | 53 |
| 2017 11 | 18 | 19 | 37 |
| 2017 10 | 17 | 18 | 35 |
| 2017 9 | 21 | 16 | 37 |
| 2017 8 | 24 | 8 | 32 |
| 2017 7 | 18 | 6 | 24 |
| 2017 6 | 25 | 21 | 46 |
| 2017 5 | 24 | 23 | 47 |
| 2017 4 | 11 | 7 | 18 |
| 2017 3 | 27 | 11 | 38 |
| 2017 2 | 9 | 11 | 20 |
| 2017 1 | 12 | 7 | 19 |
| 2016 12 | 10 | 9 | 19 |
| 2016 11 | 8 | 3 | 11 |
| 2016 10 | 5 | 3 | 8 |
| 2016 9 | 1 | 0 | 1 |
| 2016 8 | 6 | 4 | 10 |
| 2016 7 | 4 | 8 | 12 |
| 2016 6 | 0 | 5 | 5 |
| 2016 5 | 1 | 6 | 7 |
| 2016 4 | 19 | 1 | 20 |
| 2016 3 | 47 | 17 | 64 |
| 2016 2 | 41 | 26 | 67 |
| 2016 1 | 22 | 13 | 35 |
| 2015 12 | 26 | 12 | 38 |
| 2015 11 | 18 | 17 | 35 |
| 2015 10 | 26 | 31 | 57 |
| 2015 9 | 51 | 21 | 72 |
| 2015 8 | 55 | 40 | 95 |
| 2015 7 | 54 | 28 | 82 |
| 2015 6 | 69 | 36 | 105 |
| 2015 5 | 196 | 105 | 301 |
Show all
